The expression pattern of CLDN4 on circulating cancer cells denoted its potential for early diagnosis or prediction of recurrent MPE, which also shed lights on the therapeutic strategy of recurrent MPE for advanced NSCLC patients. The gene discussed is CLDN4; the disease is cancer.